Not yet recruitingPriority 3 · Moderate priorityNCT07339527
EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas
Plain-language summary
This trial is testing zeprumetostat (EZH2 inhibitor) in combination therapy for patients with extranodal NK/T-cell lymphoma (ENKTL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.
Who can join (key eligibility)
- Age 18 Years or older
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Zeprumetostat (DRUG): 350mg, po, bid | Golidocitinib (DRUG): Cohort 1: Golidocitinib: 150mg, po, qd | Chidamide (DRUG): Cohort 2: Chidamide: 20mg, po, biw
Zeprumetostat, Golidocitinib, Chidamide
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details